Danam Health Files for IPO

Ticker: WGRX · Form: S-1 · Filed: Jul 22, 2024 · CIK: 2030763

Sentiment: neutral

Topics: ipo, sec-filing, registration-statement

TL;DR

Danam Health just filed its S-1 for an IPO - get ready for a new healthcare stock!

AI Summary

Danam Health, Inc. filed an S-1 registration statement with the SEC on July 22, 2024, to register securities for a proposed sale. The company, incorporated in Delaware with principal offices in Tampa, FL, is preparing to go public. The filing details their business, financial condition, and the terms of the offering, though specific dollar amounts for the offering are not yet disclosed in this initial filing.

Why It Matters

This S-1 filing marks Danam Health's official step towards becoming a publicly traded company, providing investors with crucial information about its business and future prospects.

Risk Assessment

Risk Level: medium — As an S-1 filing, it represents a company in the process of going public, which inherently carries risks associated with market reception and early-stage business execution.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Danam Health, Inc.?

The filing does not explicitly detail the primary business of Danam Health, Inc. beyond its status as a registrant preparing for an IPO.

When was this S-1 filing submitted to the SEC?

This S-1 filing was submitted to the SEC on July 22, 2024.

Where are Danam Health, Inc.'s principal executive offices located?

Danam Health, Inc.'s principal executive offices are located at 3000 Bayport Drive Suite 950, Tampa, FL 33607.

Who is listed as an agent for service for Danam Health, Inc.?

Timothy Canning is listed as the agent for service for Danam Health, Inc.

What is the purpose of an S-1 filing?

An S-1 filing is a registration statement filed with the SEC by companies planning to offer securities to the public, providing detailed information about the company and the offering.

Filing Stats: 4,208 words · 17 min read · ~14 pages · Grade level 14.6 · Accepted 2024-07-22 16:49:30

Key Financial Figures

Filing Documents

Underwriting

Underwriting discount (1) $ $ Proceeds, before expenses, to us (2) $ $ (1) We have agreed to pay the underwriter a discount equal to 7% of the gross proceeds of the Offering. For a description of the other compensation to be received by the underwriter, see “ Underwriting ” beginning on page 104. (2) Excludes fees and expenses payable to the underwriter and other expenses of this Offering. The underwriter is offering the units on a firm commitment basis and expects to deliver the Common Stock to purchasers on or about [], 2024. EF Hutton division of Benchmark Investments, LLC The date of this prospectus is [], 2024 TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS 1 MARKET AND INDUSTRY DATA 1 FREQUENTLY USED TERMS 2 PROSPECTUS SUMMARY 5 THE OFFERING 9

RISK FACTORS

RISK FACTORS 10 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 41

USE OF PROCEEDS

USE OF PROCEEDS 42 DIVIDEND POLICY 43 CAPITALIZATION 44

SELECTED FINANCIAL DATA

SELECTED FINANCIAL DATA 46 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION 47 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF DANAM 51 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF WOOD SAGE 56 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF WELLGISTICS 61

BUSINESS

BUSINESS 68 MANAGEMENT 86

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 91 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 93 PRINCIPAL STOCKHOLDERS 95

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 96 SHARES ELIGIBLE FOR FUTURE SALE 99 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES 100

UNDERWRITING

UNDERWRITING 104 LEGAL MATTERS 108 EXPERTS 108 WHERE YOU CAN FIND MORE INFORMATION 108 INDEX TO FINANCIAL STATEMENTS F-1 DEALER PROSPECTIVE DELIVERY OBLIGATION Until [ ], all dealers that effect transactions in these securities, whether or not participating in this Offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. i ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus or in any related free-writing prospectus. We and the underwriter have not authorized anyone to provide you with information or to make any representations other than contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the underwriter take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information appearing in this prospectus, any post-effective amendment, and any applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not making an offer to sell our Common Stock in any jurisdiction where the offer or sale thereof is not permitted. You should not assume that the information appearing in this prospectus any post-effective amendment, and any applicable prospectus supplement to this prospectus is accurate as of any date other than their respective dates. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read carefully the entirety of th

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing